Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Gastroenterology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Malignant Adenoma Clinical Trials

A listing of Malignant Adenoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (14) clinical trials

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Stage I - Pharmacokinetics (Bioequivalence) Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to: Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet ...


Patients are needed to participate in a clinical research study for the treatment of Carcinoma, skin cancer, Neuroendocrine Tumor, Adenocarcinoma, melanoma

BACKGROUND Patients receiving care at the NIH Clinical Center are required to be enrolled in a clinical protocol Following participation in a treatment protocol, it may be in the best interest of the patient to continue to be followed at the Clinical Center The NCI Surgery Branch conducts clinical trials ...

Phase N/A

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...


A clinical research study for the treatment of Parathyroid Adenoma, Thyroid Adenoma, Endocrine Tumors, Malignant neoplasm of adrenal gland, Neuroblastoma

Background Endocrine neoplasms are among the fastest growing tumors in incidence in the United States. Between 1995 and 2005, the incidence of thyroid carcinoma has increased 98 percent. Tumors of the thyroid, parathyroid, adrenal gland and pancreatic neuroendocrine tumors are among some of the most difficult tumors to clinically and ...

Phase N/A

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

The trial will be conducted in 2 parts: dose escalation (Phase I ) and dose expansion (Phase 2) . Patients with unresectable or metastatic solid tumors are eligible if progressed or intolerant to prior TRK inhibitor. During Phase 1, a maximum tolerated dose (MTD)/recommended dose for further study will be ...


Assessing Outcomes in Primary or Recurrent Rectal or Sigmoid Cancer With Tumour Extending Beyond the TME Plane (Beyond TME)

Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of ...

Phase N/A

A clinical trial seeking patients for a research study for the treatment of Islet Cell Tumor, Unresectable Solid Neoplasm, Fibrolamellar Carcinoma, Ovarian Cancer, Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate safety and tolerability, determine maximum tolerated dose (MTD) and recommend a phase II dose of the combination of MLN0128 (TAK-228) (sapanisertib) with ziv-aflibercept in patients with advanced cancers refractory to standard therapy. SECONDARY OBJECTIVES: I. To give early indication of efficacy by evaluation of tumor ...


A Phase 2 clinical study for patients with Recurrent Glioma, Thyroid Adenoma, Colorectal Cancer, Lung Neoplasm, Uterine Corpus Cancer, Ovarian Cancer, Recurrent Thyroid Gland Carcinoma, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Liver Carcinoma, Pancreatic Cancer, Malignant neoplasm of kidney, Ductal Carcinoma In Situ, Recurrent Pancreatic Carcinoma, melanoma, Malignant neoplasm of prostate, bladder cancer, Advanced Malignant Solid Neoplasm, Recurrent Lymphoma, Renal Cell Carcinoma, Uterine Cancer, Endometrial Carcinoma, Malignant neoplasm of colon, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Refractory Lymphoma, Lymphoma, Breast Cancer, Cervical Cancer, Skin Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Head and Neck Carcinoma, Esophageal Carcinoma, Refractory Plasma Cell Myeloma, Recurrent Cervical Carcinoma, Multiple Myeloma, Recurrent Lung Carcinoma, Head and Neck Carcinoma, Recurrent Skin Carcinoma, Recurrent Bladder Carcinoma, Recurrent Malignant Solid Neoplasm, Rectal Cancer, Recurrent Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Glioma, Recurrent Rectal Carcinoma, Cervical Intraepithelial Neoplasia, Liver and Intrahepatic Bile Duct Carcinoma, Gastric Carcinoma, Recurrent Colorectal Carcinoma, skin cancer, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...


A clinical trial to evaluate treatments for patients with Thyroid Adenoma, Testicular Non-Seminomatous Germ Cell Tumor, Malignant Odontogenic Neoplasm, Primary Peritoneal High Grade Serous Adenocarcinoma, Bladder Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Gastric Squamous Cell Carcinoma, Transitional cell carcinoma, Urethral Adenocarcinoma, Mucinous Adenocarcinoma, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Chordoma, Appendix Mucinous Adenocarcinoma, Anal Canal Neuroendocrine Carcinoma, Lung Carcinoid Tumor, Metaplastic Breast Carcinoma, Adrenocortical carcinoma, Mucinous cystadenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Major Salivary Gland Carcinoma, Extrahepatic Bile Duct Carcinoma, Adenoid Cystic Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Nasopharyngeal Papillary Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ureter Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Placental site trophoblastic tumor, Vulvar Adenocarcinoma, Parathyroid Adenoma, Ovarian Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Rare Diseases, Paraganglioma, Pheochromocytoma, Endometrial Transitional Cell Carcinoma, Seminoma, Undifferentiated Gastric Carcinoma, Vaginal Adenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Acinar Cell Carcinoma, Pseudomyxoma Peritonei, Mesodermal mixed tumor, Islet cell carcinoma, Serous cystadenocarcinoma, Minimally Invasive Lung Adenocarcinoma, Fallopian Tube Adenocarcinoma, Ureter Adenocarcinoma, Nasopharyngeal Cancer, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Spindle Cell Neoplasm, Colorectal Squamous Cell Carcinoma, Endometrioid carcinoma, Cervical Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Esophageal Undifferentiated Carcinoma, Paranasal Sinus Cancer, Placental Choriocarcinoma, Pituitary Adenoma, Aggressive fibromatosis, Fibromyxoid Tumor, Teratoma With Malignant Transformation, Vulvar Carcinoma, Ovarian Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Penis, Urethral Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Cholangiocarcinoma, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Nasopharyngeal Undifferentiated Carcinoma, Giant cell carcinoma, Dermoid Cyst, Gastric Neuroendocrine Carcinoma, Tracheal Carcinoma, Oral Cavity Carcinoma, Nerve Sheath Tumors, Lung Sarcomatoid Carcinoma, Nasal Cavity Carcinoma, Neoplasms, Unknown Primary, Anal Canal Undifferentiated Carcinoma, gastrointestinal stromal tumor, Oropharyngeal Undifferentiated Carcinoma

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...